NASDAQ$CDXS
Codexis Inc · Q3 2020 earnings
Q3 2020 earnings · · Investor relations
Briefing
Codexis reported stronger than expected total revenues and expects higher sequential sales in the fourth quarter.
Codexis reported total revenues of $18.4 million for the third quarter of 2020. Product revenue exceeded expectations, with Merck, Allergan, and Urovant Sciences as leading contributors. The company expects full year product revenue to be above pre-COVID-19 guidance and close to 2019 levels.
- Total revenues for Q3 2020 were $18.4 million.
- Product revenue was $8.4 million, driven by Merck, Allergan and Urovant Sciences.
- R&D revenue was $10.0 million, impacted by lower revenues under the Novartis CodeEvolver® licensing agreement and a prior-year milestone payment under the GSK CodeEvolver® licensing agreement.
- Net loss for the third quarter of 2020 was $6.1 million, or $0.10 per share.
Headline financials
Revenue & EPS history
Codexis · Revenue · Quarterly
$18.4M
Forward guidance
Codexis expects higher sequential sales in the fourth quarter of 2020 and anticipates full year product revenue to be above pre-COVID-19 guidance and close to 2019 levels. The company expects to deliver 2020 total revenues near or above last year.
Tailwinds
- Expects higher sequential sales in the fourth quarter, showing growing momentum as we close 2020
- Expects full year product revenue to be above pre-COVID-19 guidance range and very close to what we delivered in 2019
- All of the growth verticals are reporting solid progress
- Expectation is to deliver 2020 total revenues near or above last year
- Positions us well for continued momentum into 2021
Headwinds
- Continuing effect of the COVID-19 pandemic on the operations of Codexis, its suppliers and customers
- Dependence on its licensees and collaborators
- Dependence on a limited number of products and customers
- Potential adverse effects to Codexis’ business if its customers’ products are not received well in the markets
- Possible impacts of the COVID-19 pandemic on Codexis’s operations and businesses and Codexis’ prospects for recovery from those impacts
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2020
-0.4%
Avg return
Earnings day
-0.0%
Avg return
5 days after
+1.2%
Avg return
30 days after
48%
31 / 64 earnings
Positive
+33.9%
Q4 2025
Best reaction
-24.5%
Q2 2012
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.0% | -4.5% | -4.5% | |
| Q4 2025 | +33.9% | +15.7% | +76.4% | |
| Q3 2025 | -4.3% | -8.9% | -26.7% | |
| Q1 2025 | +1.2% | -0.8% | -9.7% | |
| Q4 2024 | -22.6% | -30.5% | -28.5% | |
| Q3 2024 | +9.0% | +19.0% | +42.7% | |
| Q2 2024 | -7.3% | -7.3% | -9.3% | |
| Q1 2024 | +26.0% | +13.5% | +8.7% | |
| Q4 2023 | +12.0% | +1.4% | -15.9% | |
| Q3 2023 | +16.3% | +4.8% | +48.8% | |
| Q2 2023 | -10.0% | -28.7% | -43.9% | |
| Q1 2023 | -8.1% | -24.4% | -35.7% | |
| Q4 2022 | -14.0% | -12.0% | -29.5% | |
| Q3 2022 | +10.3% | +4.9% | -1.4% | |
| Q2 2022 | +12.5% | +0.0% | -13.4% | |
| Q1 2022 | -9.2% | -17.3% | -20.9% | |
| Q4 2021 | +15.9% | +13.5% | +13.1% | |
| Q3 2021 | +18.8% | +18.7% | -3.7% | |
| Q2 2021 | +17.2% | +18.6% | +29.2% | |
| Q1 2021 | -5.0% | -9.9% | -0.4% | |
| Q4 2020 | -3.4% | -1.3% | -9.6% | |
| Q3 2020 | +2.3% | +9.1% | +23.9% | |
| Q2 2020 | +6.8% | +1.9% | -4.9% | |
| Q1 2020 | +2.3% | -2.9% | +2.2% | |
| Q4 2019 | -10.2% | -12.2% | -20.6% | |
| Q3 2019 | +10.1% | +11.4% | +10.0% | |
| Q2 2019 | -14.4% | -14.9% | -15.9% | |
| Q1 2019 | -5.7% | -3.3% | -11.9% | |
| Q4 2018 | -1.6% | -5.3% | -7.7% | |
| Q3 2018 | -7.2% | -9.0% | +25.3% | |
| Q2 2018 | +4.0% | +10.4% | +32.0% | |
| Q1 2018 | +9.1% | +14.2% | +25.9% | |
| Q4 2017 | +3.3% | +18.6% | -3.3% | |
| Q3 2017 | -3.1% | -8.5% | +6.2% | |
| Q2 2017 | +5.9% | +5.0% | +10.9% | |
| Q1 2017 | +1.1% | +0.0% | -2.2% | |
| Q4 2016 | +6.0% | +8.3% | +7.1% | |
| Q3 2016 | +2.2% | +10.8% | +8.6% | |
| Q2 2016 | +2.8% | +0.0% | -4.2% | |
| Q1 2016 | +2.5% | — | — | |
| Q4 2015 | -5.9% | — | — | |
| Q3 2015 | +2.9% | — | — | |
| Q2 2015 | -3.1% | — | — | |
| Q1 2015 | -7.4% | — | — | |
| Q4 2014 | +5.4% | — | — | |
| Q3 2014 | -8.1% | — | — | |
| Q2 2014 | +7.1% | — | — | |
| Q1 2014 | +1.3% | — | — | |
| Q4 2013 | +3.1% | — | — | |
| Q3 2013 | -16.6% | — | — | |
| Q2 2013 | -12.5% | — | — | |
| Q1 2013 | +0.5% | — | — | |
| Q4 2012 | -8.5% | — | — | |
| Q3 2012 | -17.4% | — | — | |
| Q2 2012 | -24.5% | — | — | |
| Q1 2012 | -2.4% | — | — | |
| Q4 2011 | -8.7% | — | — | |
| Q3 2011 | +0.4% | — | — | |
| Q2 2011 | -9.3% | — | — | |
| Q1 2011 | -5.6% | — | — | |
| Q4 2010 | -1.5% | — | — | |
| Q3 2010 | -8.1% | — | — | |
| Q2 2010 | -5.5% | — | — | |
| Q1 2010 | -0.7% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro